摘要:
A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii)a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.
摘要翻译:用于向动物鼻内递送芬太尼或其药学上可接受的盐的组合物包括芬太尼或其药学上可接受的盐的水溶液和选自以下的药学上可接受的添加剂:(i)果胶和(ii)泊洛沙姆和壳聚糖或 其盐或衍生物; 条件是当组合物包含果胶时,其基本上不含二价金属离子; 并且与相同剂量的鼻内施用的芬太尼的简单水溶液相比,提供芬太尼(C max max)的峰值血浆浓度为10至80%,其使用简单的 芬太尼水溶液以相同的芬太尼剂量鼻内给药。 还公开了通过鼻内施用组合物治疗或治疗疼痛的方法。
摘要:
An analgesic and a delivery agent are combined in a pharmaceutical composition such that, on introduction into the nasal cavity of a patient to be treated, the analgesic may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours. The analgesic may be an opioid analgesic or a non-steroidal anti-inflammatory drug.
摘要翻译:将镇痛剂和递送剂组合在药物组合物中,使得在引入待治疗的患者的鼻腔中时,止痛剂可以在30分钟内递送到血流中,治疗血浆浓度Cther为0.2 ng / ml或更高,其保持持续至少2小时的Tmaint。 止痛剂可以是阿片样镇痛药或非甾体抗炎药。
摘要:
There is provided a composition for the nasal delivery of a cannabinoid which comprises a cannabinoid in a biphasic delivery system or a cannabinoid in a microsphere delivery system.
摘要:
A drug delivery composition for administration to mucosa is provided. The composition includes a pharmacologically active compound and particles, preferably powder or microspheres, of chitosan or a chitosan derivative or salt wherein the particles are either solidified or partially cross-linked such that they have a zeta potential of +0.5 to +50 mV. Solidified particles are made by treating particles made from a water soluble chitosan salt with an alkaline agent such as sodium hydroxide in a non-acid containing water to render them insoluble.
摘要:
Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-polyoxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours.
摘要:
A drug delivery composition for nasal administration is provided which comprises the antiviral agent ICAM-1 and a bioadhesive material. The bioadhesive material may be a chitosan solution, a liquid formulation comprising a polymeric material or a plurality of bioadhesive microspheres. The polymeric material is preferably gellan gum or alginate. The microspheres may comprise starch, chitosan, hyaluronic acid, or gelatin.
摘要:
Liquid pharmaceutical compositions for administration to a mucosal surface, comprising a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.
摘要:
Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-poly-oxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered intranasally to a patient. The buprenorphine or buprenorphine salt or ester may be delivered to the bloodstream to produce within 30 minutes a therapeutic plasma concentration of buprenorphine, Cther, of 0.2 ng/ml or greater which is maintained for a duration Tmaint of at least 2 hours.
摘要:
There is provided a composition for the nasal delivery of a drug suitable for the treatment of erectile dysfunction to a mammal wherein the composition is adapted to provide an initial rise in plasma level followed by a sustained plasma level of the drug.